


Association of serum biomarkers with radiographic knee osteoarthritis, knee pain and function in a young, male, trauma-exposed population – findings from the ADVANCE study
Running title: Serum OA biomarkers in ADVANCE

Oliver O’Sullivan, Joanne Stocks, Susie Schofield, James Bilzon, Christopher J Boos, Anthony M J Bull, Nicola T Fear, Fiona E. Watt, Alexander N. Bennett, Stefan Kluzek, Ana M. Valdes



PII: S1063-4584(24)01321-9

DOI: <https://doi.org/10.1016/j.joca.2024.07.016>

Reference: YJOCA5479

To appear in: *Osteoarthritis and Cartilage*

Received date: 13 March 2024

Accepted date: 30 July 2024

Please cite this article as: Oliver O’Sullivan, Joanne Stocks, Susie Schofield, James Bilzon, Christopher J Boos, Anthony M J Bull, Nicola T Fear, Fiona E. Watt, Alexander N. Bennett, Stefan Kluzek and Ana M. Valdes, Association of serum biomarkers with radiographic knee osteoarthritis, knee pain and function in a young, male, trauma-exposed population – findings from the ADVANCE study
Running title: Serum OA biomarkers in ADVANCE, *Osteoarthritis and Cartilage*, (2024) doi:<https://doi.org/10.1016/j.joca.2024.07.016>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Crown Copyright © 2024 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.

Title

Association of serum biomarkers with radiographic knee osteoarthritis, knee pain and function in a young, male, trauma-exposed population – findings from the ADVANCE study

Authors

Dr Oliver O'Sullivan*

Academic Department of Military Rehabilitation (ADMR), Defence Medical Rehabilitation Centre (DMRC), Stanford Hall, Loughborough

Academic Unit of Injury, Recovery and Inflammation Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham

oliver_osullivan@hotmail.com

twitter: @ollieosul

(Corresponding author)

Dr Joanne Stocks*

Academic Unit of Injury, Recovery and Inflammation Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham

Email: Joanne.Stocks@nottingham.ac.uk

Susie Schofield

National Heart and Lung Institute, Imperial College London, London, United Kingdom.

Email: s.schofield@imperial.ac.uk

Prof James Bilzon

Serum OA biomarkers in ADVANCE

Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, University of Bath,
Bath

Department for Health, University of Bath, Bath

Email: j.bilzon@bath.ac.uk

Prof Christopher J Boos

Academic Department of Military Rehabilitation (ADMR), Defence Medical Rehabilitation
Centre (DMRC), Stanford Hall, Loughborough

Faculty of Health & Social Sciences, Bournemouth University, Bournemouth

Christopher.Boos@uhd.nhs.uk

Prof Anthony M J Bull

Centre for Blast Injury Studies, Department of Bioengineering, Imperial College London,
London

a.bull@imperial.ac.uk

Prof Nicola T Fear

Academic Department of Military Mental Health, King's College London, London

nicola.t.fear@kcl.ac.uk

Dr Fiona E. Watt

Department of Immunology and Inflammation, Imperial College London, London

Centre for Osteoarthritis Pathogenesis Versus Arthritis, Kennedy Institute of Rheumatology,
University of Oxford, Oxford

Email: f.watt@imperial.ac.uk

Prof Alexander N. Bennett

Serum OA biomarkers in ADVANCE

Academic Department of Military Rehabilitation (ADMR), Defence Medical Rehabilitation Centre (DMRC), Stanford Hall, Loughborough, UK.

National Heart and Lung Institute, Imperial College London, London, UK

Email: Alexander.Bennett485@mod.gov.uk

Dr Stefan Kluzek#

Academic Unit of Injury, Recovery and Inflammation Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham

Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, University of Nottingham, Nottingham, UK

Email: Stefan.Kluzek@nottingham.ac.uk

Prof Ana M. Valdes#

Nottingham NIHR Biomedical Research Centre, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham

Department of Twin Research & Genetic Epidemiology, King's College London, London, UK

Email: Ana.Valdes@nottingham.ac.uk

*signifies joint first author

#signifies joint senior author

Running title: Serum OA biomarkers in ADVANCE

Abstract:

Objective

The Armed Services Trauma Rehabilitation Outcome (ADVANCE) study is investigating long-term combat-injury outcomes; this sub-study aims to understand the association of osteoarthritis (OA) biomarkers with knee radiographic OA (rOA), pain and function in this high-risk population for post-traumatic OA.

Design

ADVANCE compares combat-injured participants with age, rank, deployment and job-role frequency-matched uninjured participants. Post-injury immunoassay-measured serum biomarkers, knee radiographs, knee injury and osteoarthritis outcome scale (KOOS), and six-minute walk-tests (6MWT) are reported. The primary analysis, adjusted for age, body mass, socioeconomic status, and ethnicity, was to determine any differences in biomarkers between those with/without combat-injury, rOA and pain. Secondary analyses were performed to compare post-traumatic/idiopathic OA, painful/painfree rOA and injury patterns.

Results

1145 male participants were recruited, aged 34.1 ± 5.4 , 8.9 ± 2.2 years post-injury ($n=579$ trauma-exposed, of which, traumatic-amputation $n=161$) or deployment ($n=566$ matched). Cartilage oligomeric matrix protein (COMP) was significantly

higher in the combat-injured group compared to uninjured ($p=0.01$). Notably, COMP was significantly lower in the traumatic-amputation group compared to non-amputees ($p<0.001$), decreasing relative to number of amputations ($p<0.001$). Leptin was higher ($p=0.005$) and adiponectin lower ($p=0.017$) in those with v without knee pain, associated with an increased risk of 22% and 17% for pain, and 46% and 34% for painful rOA, respectively. There were no significant differences between trauma-exposed and unexposed participants with rOA.

Conclusions

The most notable findings of this large, unique study are the similarities between those with rOA regardless of trauma-exposure, the injury-pattern and traumatic-amputation-associated differences in COMP, and the relationship between adipokines and pain.

Keywords: Post-traumatic osteoarthritis, trauma, serum biomarkers, pain, ADVANCE

Introduction

Osteoarthritis (OA) is a progressive deterioration of articular cartilage and subchondral bone, associated with low-grade inflammation, altered biomechanics, and other factors, leading to a clinical syndrome of pain, stiffness, loss of function,

and increased mortality(1,2). The estimated annual medical cost of OA in the US is \$72billion(3), with an OA-related two-fold indirect cost of lost workplace productivity(4), and rising incidence; the approximate 600 million global cases of OA in 2020 are expected to double by 2050(5).

Identifying pre-clinical OA enables appropriate interventions and guides drug discovery, with molecular and imaging biomarkers employed as proxy measures to identify pathophysiological mechanisms related to extracellular matrix (ECM), inflammation or metabolic dysregulation(6-8). Cartilage-derived biomarkers, such as cartilage oligomeric protein (COMP) and C-terminal cross-linked telopeptide of type II collagen (CTX-II), are associated with OA progression and cartilage loss(9). In addition, cytokines such as interleukins (ILs) or tumour necrosis factor-alpha (TNF- α) suggest ongoing inflammatory processes, with adipokines contributing to this and indicating concurrent aberrant metabolism and systemic processes(10). A key research challenge is population heterogeneity, with biomarkers offering an opportunity for phenotyping, thus enabling personalised treatment and improved drug trial recruitment(11,12).

Post-traumatic OA (PTOA) is a widely used paradigm for biomarkers studies as it commonly presents in younger individuals with fewer co-morbidities after a clear initiating event(13,14). In addition, certain populations, including tactical and professional athletes, are at higher risk of OA due to occupational factors, including trauma(11,15-18). The prospective ArmeD SerVices TrAuma Rehabilitation OutCome (ADVANCE) cohort study was initiated to investigate the long-term outcomes of combat-injury in British service personnel following the Afghanistan

conflict (2003-2014)(19). Earlier work in this cohort has demonstrated that the amputee sub-population is a distant population from a metabolic, musculoskeletal, and psychological perspective(20-22), with an amputation conferring a 4x increased risk of OA, as did sustaining a local knee injury during the traumatic episode(22). The ADVANCE cohort offers the opportunity to develop tools for identifying those at higher risk of sequelae, such as PTOA, perhaps due to injury pattern, severity or individual predisposition, which can be translated into clinical practice. Therefore, the nested sub-study, Biomarkers and Joint Pain in Military Osteoarthritis (BioMilOA), was established to investigate the predictive value of a panel of candidate serum biomarkers associated with cartilage and ECM turnover, inflammation, and metabolism in this high-risk population for PTOA. The BioMilOA hypothesis is three-fold: there will be significant differences between those exposed and not exposed to combat trauma, those with and without radiological features of OA, and those with and without knee pain.

Methods

Study population

Eligibility criteria included male British service personnel (≥ 18 years), deployed between March 2016 and August 2020 and sustaining any combat-related traumatic injury (defined as requiring aeromedical evacuation), were recruited (n=579), with an uninjured comparison population frequency-matched for age, rank, service, deployment period, and job-role (n=566). Due to very small numbers of female UK military combat casualties and physiological sex differences, which might confound the study hypothesis, only male participants were recruited. Further details on participant identification and recruitment are found here(19,20).

Ethical approval

Favourable opinion for ADVANCE was granted by the MOD Research Ethics Committee (MODREC:357PPE12), with subsequent approval for BioMilOA from the University of Nottingham Faculty of Medicine and Health Sciences REC (FMHS 170-1122). Study participation was voluntary, and each participant provided written informed consent.

Public and Patient Involvement

PPI is regularly performed via thrice-yearly focus groups, feedback questionnaires at each visit, quarterly newsletters, participant-focussed study outcome impact reports

and the ADVANCE website (www.advancestudydmrc.org.uk). It has helped shape study design, further research questions, outcome measure recording and study logistics.

Study visits

Study visits occurred at the Defence Medical Rehabilitation Centre (DMRC) Headley Court (2015-2018) or Stanford Hall (2018-2020). A trained research nurse collected a range of assessments, including demographic data, medical history and traumatic injury, anthropometric data (height, weight, waist circumference), patient-reported outcome measures (PROMs), radiographic assessment, serum sampling and functional tests. All participants were fasted and absent from caffeine and alcohol for at least 8 hours before the visit. Body mass was corrected using an appropriate formula for missing limbs(23). The functional six-minute walk-tests (6MWT) were performed on a linear, flat 20m course, with verbal instructions before and during, asking them to walk as far as they could between two cones, but not run, for six minutes, with regular time updates. Participants could use aids and stop to rest if required, with distance recorded to the nearest 0.5m - further details on protocols used can be found here(24).

The Knee injury and OA Outcome Score (KOOS) were recorded with 5 subscales scored from 0 (very severe) to 100 (no problem), which has divergent and convergent construct validity and high test-retest reliability(25,26). Due to an error during data entry, only the KOOS Pain and KOOS Symptoms sub-scores were correctly recorded. The KOOS Pain subscale was used to determine the presence of

pain in the index knee, with participants categorised as Pain+ or Pain-. Participants were dichotomised using a cut-off of 86.1, a threshold developed by consensus in a cohort of 155 participants aged 54 ± 12 , 16 years post-meniscectomy, and validated in a prospective cohort of 1761 aged 23 (17-35) with an anterior cruciate ligament reconstruction(27,28).

Self-reported, contemporaneous combat-injury, and electronic health records (EHR) were used to classify injury patterns, including amputation (presence and number of) and local knee injury. Injured participants were coded as injured non-amputation (Inj-NA), injured amputation (Inj-A), knee injury (K-I) (when both Inj-A and K-I were present, they were coded as K-I, inline with previous analysis (22)). Study data were collected and managed using REDCap, hosted at Imperial College London, a web-based platform enabling secure and auditable data capture, export and integration into statistical and analytical software(29).

Radiographic scoring

Semi-flexed ($7-10^\circ$) posterior-anterior views of all possible participant knees were taken using a Synaflexer X-ray positioning frame (Synarc Inc, San Francisco, California). The tibiofemoral joint was scored using the Kellgren-Lawrence (KL) method, graded 0 ('none'), 1 ('doubtful'), 2 ('minimal'), 3 ('moderate') and 4 ('severe')(30). The FDA-approved Knee OA Labelling Assistant (KOALA, Image Biopsy Lab, Vienna, Austria) was utilised, with manual checking, which offers an accuracy of 82%, sensitivity of 78% and specificity of 88% for KL grades ≥ 1 (31). When participants had two variables for KL grade (from both knees), the index knee

score signifying more advanced radiographic OA (rOA) was selected (higher KL grade). For those with an above-knee amputation, the single variable was used. Radiological OA was categorised as a KL score of ≥ 1 , with participants classified as rOA+ or rOA-. This would not be expected in a population of this age and is the strongest predictor of confirmed OA(12).

Biomarker assessment

Fasted blood was taken and centrifuged at 3500rpm for 10 minutes, with serum aliquoted and stored in cryovials in monitored freezers at -80° . Sera underwent analysis for selected cartilage turnover biomarkers (COMP, CTX-II, N-propeptide of collagen IIA (PIIANP)), pro-inflammatory cytokines (IL-1 β , IL-17 α , TNF- α) and metabolic markers (leptin and adiponectin) using enzyme-linked immunosorbent assay (ELISA) or Meso Scale Discovery (MSD) by Affinity Biomarkers Lab (London, UK). This panel was selected to offer insights into some of the different pathological mechanisms underlying OA, including aberrant inflammation, tissue turnover and metabolism. Each plate included two kit controls and three internally identified quality control samples. The worst reported intra- or inter-variability coefficient of variation for each biomarker was; MSD: IL-17 α CV $< 9.5\%$, IL-1 β $< 7\%$, TNF- α $< 15\%$; ELISA: COMP $< 12\%$, Leptin $< 7\%$, Adiponectin $< 8\%$, CTX-II $< 11\%$, PIIANP $< 6\%$. For biomarker concentrations below the lower limit of quantification (LLOQ), a value halfway between zero and LLOQ threshold was selected, and for those above the upper LOQ (ULOQ), it was ULOQ threshold + 1. This was performed for IL-17 α ($< 0.54 = 0.27$, $n = 24$), PIIANP ($< 5.9 = 2.95$ $n = 23$, $> 1000 = 1001$, $n = 9$), CTX-II ($< 0.1 = 0.05$, $n = 421$), and IL-1 β ($< 0.043 = 0.0215$, $n = 713$).

Statistical analysis

Data were screened for normality visually using histograms, with parametric and non-parametric testing used accordingly. Univariate analysis was performed, depending on normality and groups (Mann-Whitney-U and Student's t or Kruskal-Wallis and analysis of variance, ANOVA). Parametric data is presented as mean \pm standard deviation (SD) and non-parametric data as median (interquartile range, IQR).

Unadjusted analyses were initially performed, followed by adjusted, with the confounders age, body mass, time from injury/deployment, rank (proxy for socio-economic status, SES(32)) and ethnicity adjusted for. This was performed by transforming the biomarkers using their natural logarithm and adjusting for the confounders using a regression model, with studentised residuals created and taken forward for analysis(33). Trauma-exposure status was additionally controlled for in the pain analysis. Within an athletic population, the body mass index (BMI) can 'overscore' individuals with a high muscle mass; therefore, a body shape index (ABSI), calculated with BMI and waist circumference, was utilised(34). Time from injury/deployment was measured from the participant's index deployment. Patient-reported and EHR were reviewed to identify those with knee pathology prior to index injury/deployment, of which there were 93 participants, 37 of whom had a specific injury associated with increased risk of OA (meniscal, cruciate, fracture), and the remainder reported persistent knee pain. Using the more conservative measure, the chi-squared test showed there were no differences between the two exposure

groups, with correlation analysis showing no notable association with biomarkers; therefore, other confounders were prioritised in the model.

Primary analysis: Do serum biomarker concentrations differ between those with/without trauma-exposure, knee rOA or pain?

- Two-group unadjusted and adjusted univariate analysis (Mann-Whitney-U/Student's t) of biomarkers, dichotomised by the presence of Exp, rOA or Pain. Specifically;
- Differences between those with and without trauma-exposure (Exp+/Exp-), knee rOA (rOA+/rOA-) and knee pain (Pain+/Pain-)

Secondary analyses: Do serum biomarker concentrations differ between those with idiopathic v PTOA, painful v painfree OA, or with different injury patterns?

- Four-, three- or two-group unadjusted and adjusted univariate analysis (Mann-Whitney-U/Student's t or Kruskal-Wallis/ANOVA) of biomarkers, dichotomised by the presence of Exp and rOA, Pain and rOA, traumatic-amputation, or the pattern of traumatic-injury, specifically;
- OA aetiology: Trauma- v non-trauma-associated OA (Exp-/rOA-, Exp-/rOA+, Exp+/rOA-, Exp+/rOA+)
- Painful OA: Painful v pain-free rOA (Pain-/rOA-, Pain+/rOA-, Pain-/rOA+, Pain+/rOA+)
- Injury pattern, amputation status: traumatic amputation vs non-traumatic amputation, stratified by number of amputations (0-3);
- Injury pattern, local knee injury: injured non-amputation (Inj-NA) vs injured amputation (Inj-A) vs knee injury (K-I)

When the adjusted analyses were significant, odds ratios (OR) were calculated using binary or multinomial logistic regression models containing the same confounders, using standardised biomarkers units (mean = 0, SD = 1), reported with 95% confidence intervals (95% CI). Finally, correlation analysis (using Spearman's or Pearson's, accordingly) was undertaken between the adjusted biomarkers and the rOA, pain, and 6MWT distance (6MWD). As all hypothesis and statistical tests were pre-planned, adjustment for multiple testing was not required(35). Significance was set at 0.05. Analyses were performed in Stata 18 (StataCorp LLC, Texas) and GraphPad Prism 10 (Dotmatics, Boston).

Results

1145 male participants were recruited, aged 26.1 ± 5.2 years at the time of injury (cases) or deployment (comparison) and 34.1 ± 5.4 years old at baseline assessment. The mean average time from deployment or injury was 8.9 ± 2.2 years. Within the cohort, 579 suffered combat-trauma (Exp+) and 566 were recruited as comparison participants (Exp-). 161 sustained a traumatic amputation (28% of Exp+); number of amputations 1 n=85, 2 n=65 and 3 n=12, respectively. Demographic data for all participants can be found in Table 1 (additional data on ethnicity and injury type can be found in Supplementary Table 1 and 2). Complete biomarker data were available for 1118 participants, and radiographic data for 1074, which are presented, alongside KOOS Pain and 6MWD, in Table 2. Participant refusal, sampling or analysis errors, and individuals with amputations account for all missing values.

Table 1 here

Table 2 here

Exposure status

Exposed participants have higher rates and more severe grades of rOA, with worse KOOS Pain scores and shorter 6MWD (all $p < 0.0001$). Unadjusted analysis showed that COMP was significantly higher in combat-trauma exposure ($p = 0.03$) (Figure 1A), remaining after adjustment for age, SES, ethnicity and time from injury ($p = 0.02$). No other biomarkers were different.

Figure 1 here

Radiographic OA change

955 participants had paired radiographic and serum data (rOA+ n=210, rOA- n=745). Those with rOA were older, had a higher BMI, and had worse KOOS Pain than those without (all $p < 0.001$). Those with rOA had significantly higher levels of leptin ($p < 0.001$) and COMP ($p = 0.005$) and significantly lower levels of PIIANP ($p = 0.001$) than those without (Table 3). After adjustment for age, body mass, ethnicity, SES and time from injury, no biomarker remained significant.

Exposure and radiographic OA change

Four groups were created, dichotomised by exposure and rOA status:

1. Exp-/rOA- (n=456, reference group)
2. Exp-/rOA+ (n=96)
3. Exp+/rOA- (n=289)
4. Exp+/rOA+ (n=114)

Unadjusted analysis revealed significant between-group differences in leptin ($p = 0.003$), COMP ($p = 0.009$) and PIIANP ($p = 0.01$). Specifically, leptin was significantly higher in Exp-/rOA+ ($p = 0.05$) and Exp+/rOA+ ($p < 0.001$) v reference, and between Exp+/rOA- and Exp+/rOA+ ($p = 0.001$); PIIANP was significantly lower in Exp-/rOA+ ($p = 0.01$) and Exp+/rOA+ ($p = 0.027$) v reference, and between Exp-/rOA+

($p=0.003$) and Exp+/rOA+ ($p=0.009$) v Exp+/rOA-; and COMP significantly higher in Exp+/rOA+ ($p=0.031$) v reference.

After adjustment for age, body mass, SES, ethnicity and time from injury, no biomarker remained significant.

Table 3 here

Knee pain status

Participants with pain were older, had increased and more severe OA, and shorter 6MWD than those without (all $p<0.001$).

Unadjusted analysis demonstrated significantly higher leptin ($p<0.0001$) and significantly lower adiponectin ($p=0.01$) in those with pain compared to those without (Table 4, Figure 2). Both remained significant after adjustment for age, body mass, SES, ethnicity, time from injury and exposure status, leptin ($p=0.001$) with an OR of 1.22 (95% CI: 1.06, 1.41) and adiponectin ($p=0.004$), OR 0.83 (95% CI: 0.71, 0.98).

Figure 2 here

Painful knee radiographic osteoarthritis

Four groups were formed, dichotomised by rOA and pain:

1. Pain-/rOA- (n=483, reference group)

2. Pain+/rOA- (n=258)
3. Pain-/rOA+ (n=103)
4. Pain+/rOA+ (n=104)

Those with Pain+/rOA+ had higher BMI and reduced 6MWD (both $p < 0.001$) (Table 4). Unadjusted analysis demonstrated significant between-group differences for COMP ($p = 0.05$), adiponectin ($p = 0.01$) and leptin ($p < 0.001$). Specifically, there were non-significant differences for COMP; significantly lower adiponectin in Pain+/rOA+ v reference ($p = 0.03$) and Pain-/rOA+ ($p = 0.02$); and significantly higher leptin in Pain+/rOA- ($p = 0.001$) and in Pain+/rOA+ v all groups (reference $p < 0.001$, Pain+/rOA- and Pain-/rOA+ both $p = 0.006$).

After adjustment for age, body mass, SES, ethnicity, time from injury and exposure status, adiponectin ($p = 0.017$) and leptin ($p = 0.006$) remained significant, with significantly lower adiponectin in Pain+/rOA+ ($p = 0.028$), and significantly higher leptin in Pain+/rOA- ($p = 0.007$) and Pain+/rOA+ (v reference $p = 0.001$, and Pain-/rOA+ $p = 0.05$). Leptin and adiponectin ORs for Pain+/rOA+ from the reference group were 1.46 (95% CI: 1.19, 1.79) and 0.66 (95% CI: 0.45, 0.98), respectively.

Table 4 here

Associations between the biomarkers and radiographic change, pain and function

There were statistically significant correlations between four biomarkers (adjusted for age, body mass, SES, ethnicity, and time from injury), and rOA, pain and/or 6MWD.

Leptin had a correlation coefficient of 0.12 ($p < 0.001$) with knee pain and -0.11 ($p < 0.001$) with 6MWD, adiponectin of -0.08 ($p = 0.01$) with pain, TNF- α of -0.08 ($p = 0.01$) with 6MWD, and PIIANP -0.06 ($p = 0.05$) with rOA (Figure 3).

Figure 3 here

Amputation status

Within the exposed group, data were available for those with ($n = 156$) and without ($n = 409$) traumatic amputation. Those with a traumatic amputation achieved a lower 6MWD ($p < 0.001$).

Unadjusted analysis revealed significantly lower COMP in traumatic amputation ($p < 0.001$), which remained significant after adjustment for age, body mass, SES, ethnicity and time from injury ($p < 0.001$), compared to those without a traumatic amputation (Figure 1b).

The levels of COMP reduced relative to the number of amputations; none ($n = 409$) 264.2 (217.6-322.8), one ($n = 81$) 232.8 (180.4-280.4), two ($n = 63$) 167.4 (137.9-206.9), three ($n = 12$) 132.9 (118.6-184.2), $p < 0.001$ (Figure 4).

Figure 4 here

In those with an amputation who had radiographs ($n = 94$), those with rOA ($n = 40$) showed significantly higher CTX-II ($p = 0.009$) and significantly lower IL-17 α ($p = 0.03$)

than without (n=54) in unadjusted analysis (Supplementary Table 3). Only IL-17 α remained significant after adjustment for age, body mass, SES, ethnicity and time from injury (p=0.02).

In those with an amputation, serum and KOOS Pain scores (n=105) showed no differences between those with (Pain+, n=41) or without pain (Pain-, n=64).

Specific knee injury

Within the exposed group with serum (n=565), three groups were formed;

1. Inj-NA (n=389, reference group)
2. Inj-A (n=141)
3. K-I (n=35)

Two biomarkers were significant on unadjusted analysis (COMP, p<0.001 and leptin, p=0.02) (Supplementary Table 4). COMP was significantly lower in Inj-A (209.0 \pm 76.1ug/l, p<0.001) and K-I (243.3 \pm 69.0ug/l, p=0.03) v reference (280.3 \pm 86.2ug/l), which remained significant after adjustment (Inj-A p<0.001, K-I p=0.05). Those with K-I had significantly higher leptin (8.68ug/l, IQR: 4.57-12.86) than reference (5.68ug/l, IQR: 3.16-9.37, p=0.003) and Inj-A (6.1ug/l, IQR: 3.26-11.67, p=0.02), which after adjustment, remained significant for K-I v reference (p=0.003) and Inj-A (p=0.009). COMP had a non-significant OR and leptin an OR of 1.33 (95% CI: 1.09,1.63) for rOA after K-I.

Discussion

This is the largest study investigating candidate biomarkers of early OA in a young, physically active, homogenous male population at high risk for PTOA. It has several key findings. COMP was significantly higher following combat-injury compared to non-injured participants, but significantly lower in those with a traumatic-amputation compared to non-amputees, proportional to the number of amputations. To the author's knowledge, this is the first description of such a finding. Remarkably, there were no differences between those with trauma-exposed rOA v non-trauma-exposed rOA. Increased leptin and decreased adiponectin were associated with an increased risk of knee pain of 22% and 17%, and painful rOA 46% and 34%, respectively. There were weak correlations between PIIANP with rOA, leptin and adiponectin with pain, and leptin and TNF- α with 6MWD. An initial local knee injury influenced outcomes, with those sustaining a traumatic knee injury having higher levels of leptin compared to other trauma-exposed participants, associated with a 33% risk of rOA, and lower levels of COMP compared to trauma-exposed non-amputees.

Understanding the molecular picture following trauma is important, which, given the frequency and severity similarities of polytrauma following road traffic accidents, is a generalisable research question(36). Only one biomarker, COMP, was significantly different, suggesting that COMP may play a role in the body's response to injury and maintenance of cartilage integrity. COMP, a collagen-network stabiliser binding type I and type II collagen fibres mainly expressed by cartilage(37), is associated with OA(9)and other conditions including liver, lung, and skin fibrosis(37,38). It is possible, therefore, that the increase in COMP is representative of fibrosis following

trauma, which might have implications for future joint and cardiovascular health(20). While a traumatic amputation is likely to lead to significant fibrosis, it will also reduce the cartilage volume to synthesise it. This study reports, for the first time, significantly lower COMP following traumatic-amputation, quantified by the number of amputated limbs. This is a notable finding, providing evidence of cartilage volume in COMP synthesis, which, by extension, also includes cartilage health, and this is supported by those with a local knee injury having lower COMP levels. The lack of significant difference between those who sustained two and three amputated limbs is likely due to upper-limb involvement, with resultant reduced cartilage loss volume. COMP levels seen in traumatic amputations are lower than a US military combat amputee population, although this could be due to their far smaller numbers (n=31)(39).

One of this study's most striking results comes from the analysis stratified by exposure and rOA. The pre-specified hypothesis was that there would be a difference between those developing OA following trauma-exposure compared to the unexposed, predicated on the traumatic-dominant mechanism displaying a significantly different molecular pattern to an idiopathic-dominant (albeit accelerated) pattern. This was not what was found. However, these surprising results were in keeping with genetic studies that have yet to find differences between idiopathic and PTOA(40,41) and animal models postulating idiopathic and PTOA share a common 'mechanoinflammation' mechanism(42). This finding, if validated in other populations, would enable results from PTOA studies to be extrapolated across all OA research fields.

The next area was the differences in serum biomarkers between those with and without rOA. $KL \geq 1$ was selected purposefully as the criteria as the strongest predictor of diagnosed OA(12), especially in this young population where rOA should not be present. Although leptin, COMP and PIIANP were significantly different in unadjusted analysis, no biomarkers remained significant after adjustment for age, body mass, SES and ethnicity (all independent risk factors for OA development and progression(1,11,43)). The lack of significant results might reflect their fluid type or be related to the time from injury, as the evidence is poor regarding the utility of serum biomarkers over a year from injury(6). A recent review by the study authors synthesised all biomarkers measured a year or more from injury, reporting eight studies with 879 participants(6). 38 serum biomarkers were measured, and only three (cleavage of type II collagen, hyaluronic acid, N-telopeptide of type I collagen) had a relationship to rOA, and one (TNF) to pain (also, like this study, measured by KOOS)(6). This suggests that biomarkers acknowledged to have value in the early stage following injury might not have the same value later in the disease course, and further evidence is required to understand this(6,8,44). In addition, CTX-II, selected by the Foundation for the National Institutes of Health (FNIH) OA Biomarkers Consortium (BC) as a candidate marker(8) was measured using the serum, not the urinary form, which might explain the results.

Early identification of individuals with painful OA is essential, given pain is the primary symptom, the leading cause of medical consultation and very complex to manage(45,46). In this study, both leptin and adiponectin were associated with an increased risk of developing knee pain and painful knee rOA. Leptin is believed to have a role in cartilage degeneration through cytokine mediation and synthesis of

cartilage proteoglycan(40), with animal studies demonstrating that deletion of the leptin gene prevents OA development(47). Adiponectin has been seen to have an anti-inflammatory effect and, in addition, analgesic properties through inhibition of p-p38 MAPK signalling(48). These findings are consistent with the understanding that adipokines can influence pain via serotonin, inflammatory and metabolic pathways(48,49); therefore, potentially, they could be used to identify and categorise a painful OA phenotype. The increased leptin levels in those with a local knee injury suggest that this biomarker may offer some increased value for the knee joint specifically. It is important to note that these differences, whilst statistically significant, are small and therefore of uncertain clinical significance but do generate hypotheses for further analysis.

Ultimately, the value of any biomarker is the ability to detect predetermined outcomes and quantify the pathophysiological process in question. Correlation analyses between all biomarkers and key outcome measures, rOA, knee pain, and 6MWD, showed limited cross-sectional value. Only PIIANP correlated with rOA, leptin and adiponectin to pain, and leptin and TNF- α to function, with all correlations weak ($r = -0.11-0.12$). As described above, these findings could be partly explained by both time from injury and biomarker type, with further work required to understand their value and potential roles(6,44).

The key strength of this study is its design; large numbers ($n=1145$), and frequency-matched comparison population. Additionally, the median time from injury is beyond the five-year period suggested by UK BioBank as highest risk for PTOA(40). The study's key limitation is that all participants are young and male. This population is

relatively under-researched in OA research with many studies involving postmenopausal females, and therefore fills an unmet need, however, validation of findings might be challenging. Outside of the amputee groups, populations drawn from recreational or elite sports or other military populations, including the US(39), are comparable and potentially able to validate findings. Further weaknesses are the ELISA floor and ceiling effect, particularly CTX-II and IL-1 β , which had 37% and 60% of values below the LLOQ, and the single radiographic view of the knee, which may underscore rOA.

This study reports the differences between those exposed and not exposed to combat trauma, rOA, and pain in a young, physically active population at high risk for PTOA. Significant findings include, contrary to the predetermined hypothesis, a lack of difference between those with early-onset idiopathic OA and a PTOA presentation, a quantification of the relationship between traumatic amputation (and therefore cartilage synthesis) to COMP, and the potential value of adipokines for both painful OA phenotyping and identification of pain and functional outcomes.

Acknowledgements

We wish to thank all of the research staff at both Headley Court and Stanford Hall who helped with the ADVANCE study, including Emma Coady, Eleanor Miller and Owen Walker. Furthermore, we thank all who serve, especially those who continue to within ADVANCE.

Contributions

ANB, CJB, NTF, and AMJB conceived the study. OOS and ANB gathered data. JS undertook study logistics. OOS analysed the data with support from SS, AV, JS, and SK. OOS drafted the manuscript, with critical input from all authors. FW and JB, alongside SK and ANB, provided strategic direction and senior guidance. All authors agreed the final version and are accountable for accuracy and integrity. OOS acts as the guarantor and corresponding author.

Role of funding sources

BioMilOA was funded by a grant from Versus Arthritis (21076), with additional funding from the UK Ministry of Defence (2122.030). The ADVANCE Study is funded through the ADVANCE Charity. Key contributors to the charity are the Headley Court Charity (principal funder), HM Treasury (LIBOR Grant), Help for Heroes, Nuffield Trust for the Forces of the Crown, Forces in Mind Trust, National Lottery Community Fund, Blesma – The Limbless Veterans, and the UK Ministry of Defence. FW is funded by a fellowship from UK Research & Innovation

(MR/S016538/1;MR/S016538/2;MR/Y003470/1). JB is the director of the Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, of which FW and SK are members (funded by Versus Arthritis, 21595). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript.

Competing interests

There are no competing interests to declare.

Declaration of generative AI in scientific writing

No AI technology was used during the study or preparation of this manuscript.

Data availability

Data relate to serving and ex-serving military personnel and thus are sensitive and have not been made widely available. Requests for data can be made via the corresponding author can will be considered on a case-by-case basis and subject to UK Ministry of Defence clearance. The ADVANCE study protocol is available online. Code used for analysis will be shared on request to the corresponding author.

References

1. Mobasheri A, Batt M. An update on the pathophysiology of osteoarthritis. *Annals of physical and rehabilitation medicine*. 2016;59(5-6):333-9.
2. Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Jüni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. *BMJ*. 2011;342:d1165.
3. Leifer VP, Katz JN, Losina E. The burden of OA-health services and economics. *Osteoarthritis and Cartilage*. 2022;30(1):10-6.
4. DiBonaventura Md, Gupta S, McDonald M, Sadosky A. Evaluating the health and economic impact of osteoarthritis pain in the workforce: results from the National Health and Wellness Survey. *BMC musculoskeletal disorders*. 2011;12:1-9.
5. Steinmetz JD, Culbreth GT, Haile LM, Rafferty Q, Lo J, Fukutaki KG, *et al*. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet Rheumatology*. 2023;5(9):e508-e22.
6. O'Sullivan O, Ladlow P, Steiner K, Hillman C, Stocks J, Bennett AN, *et al*. Current status of catabolic, anabolic and inflammatory biomarkers associated with structural and symptomatic changes in the chronic phase of post-traumatic knee osteoarthritis– a systematic review. *Osteoarthritis and Cartilage Open*. 2023;5(4):100412.
7. Kim H, Seo J, Lee Y, Park K, Perry TA, Arden NK, *et al*. The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities. *Therapeutic Advances in Musculoskeletal Disease*. 2022;14:1759720X221085952.
8. Hunter DJ, Collins JE, Deveza L, Hoffmann SC, Kraus VB. Biomarkers in osteoarthritis: current status and outlook — the FNHIH Biomarkers Consortium PROGRESS OA study. *Skeletal Radiology*. 2023;52(11):2323-39.
9. Valdes AM, Meulenbelt I, Chassaing E, Arden N, Bierma-Zeinstra S, Hart D, *et al*. Large scale meta-analysis of urinary C-terminal telopeptide, serum cartilage oligomeric protein and matrix metalloprotease degraded type II collagen and their role in prevalence, incidence and progression of osteoarthritis. *Osteoarthritis and cartilage*. 2014;22(5):683-9.
10. Robinson WH, Lepus CM, Wang Q, Raghu H, Mao R, Lindstrom TM, *et al*. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. *Nat Rev Rheumatol*. 2016;12(10):580-92.
11. O'Sullivan O, Behan FP, Coppack RJ, Stocks J, Kluzek S, Valdes AM, *et al*. Osteoarthritis in the UK Armed Forces: a review of its impact, treatment and future research. *BMJ Military Health*. 2023:e002390.
12. Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. *Osteoarthritis and Cartilage*. 2015;23(8):1233-41.
13. Watt FE. Posttraumatic osteoarthritis: what have we learned to advance osteoarthritis? *Current Opinion in Rheumatology*. 2021;33(1):74-83.
14. O'Sullivan O, Ladlow P, Steiner K, Kuyser D, Ali O, Stocks J, *et al*. Knee MRI biomarkers associated with structural, functional and symptomatic changes at least a year from ACL injury - A systematic review. *Osteoarthritis and Cartilage Open*. 2023:100385.

15. Cameron KL, Driban JB, Svoboda SJ. Osteoarthritis and the Tactical Athlete: A Systematic Review. *J Athl Train*. 2016;51(11):952-61.
16. Fernandes GS, Parekh SM, Moses J, Fuller C, Scammell B, Batt ME, *et al*. Prevalence of knee pain, radiographic osteoarthritis and arthroplasty in retired professional footballers compared with men in the general population: a cross-sectional study. *British Journal of Sports Medicine*. 2018;52(10):678.
17. Rivera JC, Wenke JC, Buckwalter JA, Ficke JR, Johnson AE. Posttraumatic Osteoarthritis Caused by Battlefield Injuries: The Primary Source of Disability in Warriors. *JAAOS - Journal of the American Academy of Orthopaedic Surgeons*. 2012;20:S64-S9.
18. Golightly YM, Shiue KY, Nocera M, Guermazi A, Cantrell J, Renner JB, *et al*. Association of Traumatic Knee Injury with Radiographic Evidence of Knee Osteoarthritis in Military Officers. *Arthritis Care & Research*. 2023;75(8):1744-51.
19. Bennett AN, Dyball DM, Boos CJ, Fear NT, Schofield S, Bull AM, *et al*. Study protocol for a prospective, longitudinal cohort study investigating the medical and psychosocial outcomes of UK combat casualties from the Afghanistan war: the advance study. *BMJ open*. 2020;10(10):e037850.
20. Boos CJ, Schofield S, Cullinan P, Dyball D, Fear NT, Bull AM, *et al*. Association between combat-related traumatic injury and cardiovascular risk. *Heart*. 2022;108(5):367-74.
21. Dyball D, Bennett AN, Schofield S, Cullinan P, Boos CJ, Bull AM, *et al*. Mental health outcomes of male UK military personnel deployed to Afghanistan and the role of combat injury: analysis of baseline data from the ADVANCE cohort study. *The Lancet Psychiatry*. 2022;9(7):547-54.
22. Behan FP, Bennett AN, Watson F, Schofield S, O'Sullivan O, Boos CJ, *et al*. Osteoarthritis after major combat trauma: The Armed Services Trauma Rehabilitation Outcome Study *Rheumatology*. 2024.
23. Tzamaloukas AH, Patron A, Malhotra D. Body mass index in amputees. *JPEN J Parenter Enteral Nutr*. 1994;18(4):355-8.
24. O'Sullivan O, Felton J, McLean S, Bennett AN. Six-minute walk test in healthy British service personnel. *BMJ Military Health*. 2024:e002720.
25. Collins NJ, Misra D, Felson DT, Crossley KM, Roos EM. Measures of knee function: International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale (KOS-ADL), Lysholm Knee Scoring Scale, Oxford Knee Score (OKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Activity Rating Scale (ARS), and Tegner Activity Score (TAS). *Arthritis care & research*. 2011;63(S11):S208-S28.
26. Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. *Health and quality of life outcomes*. 2003;1(1):1-8.
27. Englund M, Roos EM, Lohmander LS. Impact of type of meniscal tear on radiographic and symptomatic knee osteoarthritis: A sixteen-year followup of meniscectomy with matched controls. *Arthritis & Rheumatism*. 2003;48(8):2178-87.
28. Wasserstein D, Huston LJ, Nwosu S, Kaeding CC, Parker RD, Wright RW, *et al*. KOOS pain as a marker for significant knee pain two and six years after primary ACL reconstruction: a Multicenter Orthopaedic Outcomes Network (MOON) prospective longitudinal cohort study. *Osteoarthritis Cartilage*. 2015;23(10):1674-84.

29. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377-81.
30. Kellgren JH, Lawrence J. Radiological assessment of osteo-arthritis. *Annals of the rheumatic diseases.* 1957;16(4):494.
31. Nehrer S, Ljuhar R, Steindl P, Simon R, Maurer D, Ljuhar D, *et al.* Automated Knee Osteoarthritis Assessment Increases Physicians' Agreement Rate and Accuracy: Data from the Osteoarthritis Initiative. *Cartilage.* 2021;13(1_suppl):957s-65s.
32. Office for National Statistics. SOC 2020 Volume 3: the National Statistics Socio-economic Classification (NS-SEC rebased on the SOC 2020) 2021 [Available from: <https://www.ons.gov.uk/methodology/classificationsandstandards/standardoccupationalclassificationandstandards/soc2020/soc2020volume3thenationalstatisticsocioeconomicclassificationnssecbasedonthesoc2020>].
33. Martinez MN, Bartholomew MJ. What Does It "Mean"? A Review of Interpreting and Calculating Different Types of Means and Standard Deviations. *Pharmaceutics.* 2017;9(2).
34. Bertoli S, Leone A, Krakauer NY, Bedogni G, Vanzulli A, Redaelli VI, *et al.* Association of Body Shape Index (ABSI) with cardio-metabolic risk factors: A cross-sectional study of 6081 Caucasian adults. *PLoS One.* 2017;12(9):e0185013.
35. Rothman KJ. No adjustments are needed for multiple comparisons. *Epidemiology.* 1990;1(1):43-6.
36. Mullen S, Tolson A, Bourama O, Watson B, Lyttle MD, Roland D, *et al.* Comparison of injury patterns and interventions between adolescent, adult and paediatric trauma cases: a cross-sectional review of TARN data. *BMJ Open.* 2023;13(5):e064101.
37. Zachou K, Gabeta S, Shums Z, Gatselis NK, Koukoulis GK, Norman GL, *et al.* COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. *European Journal of Internal Medicine.* 2017;38:83-8.
38. Yamamoto M, Takahashi H, Suzuki C, Naishiro Y, Yamamoto H, Imai K, *et al.* Cartilage oligomeric matrix protein in systemic sclerosis. *Rheumatology.* 2007;46(12):1858-9.
39. Wasser JG, Hendershot BD, Acasio JC, Krupenevich RL, Pruziner AL, Miller RH, *et al.* A Comprehensive, Multidisciplinary Assessment for Knee Osteoarthritis Following Traumatic Unilateral Lower Limb Loss in Service Members. *Military Medicine.* 2024;189(3-4):581-91.
40. Hollis B, Chatzigeorgiou C, Southam L, Hatzikotoulas K, Kluzek S, Williams A, *et al.* Lifetime risk and genetic predisposition to post-traumatic OA of the knee in the UK Biobank. *Osteoarthritis Cartilage.* 2023;31(10):1377-87.
41. Valdes AM, Doherty SA, Muir KR, Wheeler M, Maciewicz RA, Zhang W, *et al.* The genetic contribution to severe post-traumatic osteoarthritis. *Annals of the rheumatic diseases.* 2013(72):1687-90.
42. Vincent TL. Of mice and men: converging on a common molecular understanding of osteoarthritis. *The Lancet Rheumatology.* 2020;2(10):e633-e45.
43. Whittaker JL, Losciale JM, Juhl CB, Thorlund JB, Lundberg M, Truong LK, *et al.* Risk factors for knee osteoarthritis after traumatic knee injury: a systematic review and meta-analysis of randomised controlled trials and cohort studies for the OPTIKNEE Consensus. *British journal of sports medicine.* 2022;56(24):1406-21.
44. Kraus VB, Karsdal MA. Clinical monitoring in osteoarthritis: Biomarkers. *Osteoarthritis and Cartilage.* 2022;30(9):1159-73.
45. Neogi T. The epidemiology and impact of pain in osteoarthritis. *Osteoarthritis and cartilage.* 2013;21(9):1145-53.

46. Neelapala YVR, Neogi T, Kumar D, Jarraya M, Macedo L, Kobsar D, *et al.* Exploring different models of pain phenotypes and their association with pain worsening in people with early knee osteoarthritis: The MOST cohort study. *Osteoarthritis and Cartilage*. 2024;32(2):210-9.
47. Griffin TM, Huebner JL, Kraus VB, Guilak F. Extreme obesity due to impaired leptin signaling in mice does not cause knee osteoarthritis. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology*. 2009;60(10):2935-44.
48. Gao S-J, Liu D-Q, Li D-Y, Sun J, Zhang L-Q, Wu J-Y, *et al.* Adipocytokines: Emerging therapeutic targets for pain management. *Biomedicine & Pharmacotherapy*. 2022;149:112813.
49. Yan M, Zhang J, Yang H, Sun Y. The role of leptin in osteoarthritis. *Medicine (Baltimore)*. 2018;97(14):e0257.




Figure 1. Differences in concentrations of cartilage oligomeric matrix protein (COMP) between those unexposed and exposed to combat trauma (a) and within those exposed to combat trauma, those without and with a traumatic amputation (b) Values in (ug/l), shown with median (IQR), test used Student's t test




Figure 2. Differences in leptin (a) and adiponectin (b) between those not reporting and reporting knee pain
 Leptin values in ug/l, adiponectin mg/l, shown with median (IQR), test used Student's t and Mann-Whitney-U




Figure 3. Heatmap demonstrating the correlations between the panel of fully adjusted biomarkers and the presence of early radiographic osteoarthritis change, the presence of knee pain and the distance achieved on the six-minute walk test.
 Spearman or Pearson's correlation, depending on normality




Figure 4. Differences in levels of cartilage oligomeric protein stratified by quantity of traumatic limb amputations

Values in (ug/l), shown with median (IQR), test used oneway analysis of variance

Table 1. Demographic data for all participants, stratified by exposure (Exp-/Exp+) and amputation status

	Total	Unexposed (Exp-)	All	Exposed (Exp+)	
	N=1,145	N=566	N=579	No Amputation N=418	Amputation N=161
Age	34.1	34.2	34.0	34.4	33.0
Mean (SD)	(5.4)	(5.4)	(5.3)	(5.6)	(4.6)
Body Mass Index	27.8	27.4	28.1	27.9	28.8
Mean (SD)	(3.7)	(3.4)	(3.9)	(3.7)	(4.4)
Abdo. Circum.(cm)	93.5 (88.0-101.0)	92.0 (87.0-100.0)	94.0 (88.0-102.0)	94.0 (88.0-102.0)	95.0 (89.0-104.0)
Median (IQR)					
Caucasian N (%)	1008 (88%)	494 (87%)	514 (89%)	370 (89%)	144 (89%)
Rank N (%)					
Junior NCO	754 (66%)	340 (60%)	414 (72%)	286 (68%)	128 (80%)
Senior NCO	253 (22%)	147 (26%)	106 (18%)	86 (21%)	20 (12%)
Officer	138 (12%)	79 (14%)	59 (10%)	46 (11%)	13 (8%)
NISS	12	-	12	9	25
Median (IQR)	(5-22)		(5-22)	(4-17)	(17-24)
Time from injury / deployment	8.9	8.8	8.9	9.2	8.1
Mean (SD)	(2.2)	(2.2)	(2.2)	(2.2)	(2.1)

SD – standard deviation, IQR – interquartile range, Abdo. – abdominal, circum. – circumference, cms – centimetres, NCO – non-commissioned officer, NISS – New Injury Severity Scale

Serum OA biomarkers in ADVANCE

Table 2. Biomarker, radiographic, patient-reported and functional outcomes for all participants, stratified by exposure (Exp-/Exp+) and amputation status

	Total N=1,118	Unexposed (Exp-) N=553	Exposed (Exp+)		p-value Unadj. Adj.
			No Amputation N=409	Amputation N=156	
IL1β (ng/l)	0.0	0.0	0.0	0.0	0.592~
Median (IQR)	(0.0-0.1)	(0.0-0.1)	(0.0-0.1)	(0.0-0.1)	0.528~
TNFα (ng/l)	1.9	1.9	1.9	1.9	0.818^
Mean (SD)	(\pm 0.6)	(\pm 0.6)	(\pm 0.5)	(\pm 0.4)	0.736^
IL17α (ng/l)	1.3	1.3	1.3	1.3	0.756~
Median (IQR)	(1.0-1.8)	(1.0-1.8)	(1.0-1.8)	(1.0-1.9)	0.945~
CTXII (ug/l)	0.2	0.2	0.2	0.1	0.661~
Median (IQR)	(0.1-0.6)	(0.1-0.7)	(0.1-0.6)	(0.1-0.7)	0.771~
Leptin (ug/l)	5.7	5.5	5.7	6.3	0.070~
Median (IQR)	(3.0-9.3)	(3.0-8.8)	(3.2-9.6)	(3.2-11.8)	0.361~
COMP (ug/l)	263.6	267.1	279.5	209.3	<0.001^
Mean (SD)	(\pm 88.6)	(\pm 88.8)	(\pm 85.6)	(\pm 74.3)	<0.001^
Adipo (mg/l)	6.3	6.2	6.6	6.1	0.350^
Mean (SD)	(\pm 4.5)	(\pm 4.0)	(\pm 5.1)	(\pm 4.2)	0.731^
PIIANP (ug/l)	109.1	109.2	110.5	105.8	0.333~
Median (IQR)	(73.9-160.1)	(74.6-157.3)	(73.8-168.3)	(71.5-151.1)	0.364~
KL\geq1 N (%)	250 (23.8%)	96 (17.4%)	114 (28.3%)	40 (42.6%)	<0.001~
Index knee KL Grade N (%)					<0.001~
0	799 (71%)	456 (82%)	289 (71%)	55 (35%)	
1	147 (13%)	59 (11%)	65 (16%)	23 (15%)	
2	74 (7%)	26 (5%)	35 (9%)	13 (8%)	
3	26 (2%)	9 (2%)	13 (3%)	4 (3%)	
4	3 (0%)	2 (0%)	1 (0%)	0 (0%)	
Missing	69 (6%)	1 (0%)	6 (1%)	62 (40%)	
Index knee KOOS Pain	92	94	89	92	<0.001~
Median (IQR)	(78-100)	(83-100)	(72-100)	(78-100)	
KOOS Pain <86.1 N (%)	405 (38%)	179 (33%)	185 (46%)	41 (39%)	<0.001~
6MWD	599	631	593	488	<0.001^
Mean (SD)	(\pm 117)	(\pm 96)	(\pm 118)	(\pm 121)	

IL – Interleukin, TNF – Tumour Necrosis Factor, CTX-II – C-terminal cross-linked telopeptide of type II collagen, COMP – cartilage oligomeric protein, PIIANP – N-propeptide of collagen IIA, Adipo – Adiponectin, KL – Kellgren-Lawrence, KOOS – Knee Injury and Osteoarthritis Outcome Score, 6MWT – Six-minute walk-test distance, 95% CI – 95% confidence interval, Unadj. – unadjusted, Adj. - Adjusted

^three group oneway analysis of variance ~three group Kruskal-Wallis, dichotomised by exposure and amputation status

Table 3. Demographic and outcome differences between those with and without knee radiographic osteoarthritis changes (rOA-/rOA+), further stratified by exposure status (Exp-/Exp+)

	Total	rOA -	rOA +	p- value Unadj. /Adj.	Exp- /rOA-	Exp- /rOA+	Exp+/r OA-	Exp+/r OA+	p-value Unadj./Adj.
--	-------	----------	----------	--------------------------------	---------------	---------------	---------------	---------------	------------------------

Serum OA biomarkers in ADVANCE

	N=955	N=7 45	N=2 10		N=456	N=96	N=289	N=114	
Age	34.3	33.	36.	<0.001	33.7	36.7	33.6	36.3	<0.001 [^]
Mean (SD)	(± 5.5)	7 (± 5.2)	5 (± 5.9)	#	(± 5.2)	(± 6.0)	(± 5.3)	(± 5.8)	
BMI	27.6	27.	28.	<0.001	27.2	28.3	27.4	29.0	<0.001 [^]
Mean (SD)	(± 3.5)	3 (± 3.3)	7 (± 3.8)	#	(± 3.3)	(± 3.5)	(± 3.4)	(± 3.9)	
IL1β (ng/l)	0.0	0.0	0.0	0.469 ^{''} 0.405	0.0	0.0	0.0	0.0	0.788~ 0.735~
Median (IQR)	(0.0- 0.1)	- 0.1)	- 0.1)		(0.0- 0.1)	(0.0- 0.1)	(0.0- 0.1)	(0.0- 0.1)	
TNFα (ng/l)	1.9	1.9	1.9	0.686# 0.798	2.0	1.9	1.9	2.0	0.784 [^] 0.863 [^]
Mean (SD)	(± 0.6)	(± 0.6)	(± 0.5)		(± 0.7)	(± 0.4)	(± 0.6)	(± 0.5)	
IL17α (ng/l)	1.3	1.3	1.3	0.071 ^{''} 0.172	1.3	1.3	1.3	1.4	0.331~ 0.535~
Median (IQR)	(1.0- 1.8)	- 1.8)	- 2.0)		(0.9- 1.8)	(1.0- 1.9)	(1.0- 1.7)	(1.0- 2.1)	
CTXII (ug/l)	0.2	0.2	0.2	0.186 ^{''} 0.709	0.2	0.4	0.2	0.2	0.412~ 0.819~
Median (IQR)	(0.1- 0.6)	- 0.6)	- 0.7)		(0.1- 0.7)	(0.1- 0.8)	(0.1- 0.6)	(0.1- 0.6)	
Leptin (ug/l)	5.6	5.3	6.6	<0.001 ^{''} 0.075	5.3	6.1	5.3	7.0	0.003~ 0.227~
Median (IQR)	(3.0- 9.1)	(2.9- 8.7)	- 10. 1)		(2.8- 8.7)	(3.5- 9.1)	(2.9- 8.7)	(4.2- 11.6)	
COMP (ug/l)	272.5	268	287	0.005# 0.789	263.4	285.6	275.9	289.0	0.009 [^] 0.116 [^]
Mean (SD)	(± 87.8)	86. (± 3)	91. (± 6)		(± 86.8)	(± 96.0)	(± 85.0)	(± 88.1)	
Adipo (mg/l)	6.4	6.4	6.1	0.289# 0.151	6.3	5.8	6.7	6.3	0.386 [^] 0.353 [^]
Mean (SD)	(± 4.5)	(± 4.4)	(± 5.0)		(± 4.2)	(± 3.1)	(± 4.7)	(± 6.2)	
PIIANP (ug/l)	109.9	115.	96.	0.001 ^{''} 0.045	114.7	95.5	115.6	96.8	0.010~ 0.579~
Median (IQR)	(73.9- 162.5)	0- 168 .5)	2- 144 .2)		(75.8- 163.9)	(71.0- 141.1)	(81.8- 178.3)	(68.7- 150.1)	
Index knee KOOS Pain	94	94	86	<0.001 ^{''} "	97	89	92	86	<0.001~
Median (IQR)	(81- 100)	(81- 100)	(69- 100)		(83- 100)	(75- 100)	(75- 100)	(67- 100)	
6MWD	615	617	609	0.35#	629	637	597	585	<0.001 [^]
Mean (SD)	(± 106)	(± 106)	(± 106)		(± 95)	(± 100)	(± 119)	(± 106)	

IL – Interleukin, TNF – Tumour Necrosis Factor, CTX-II - C-terminal cross-linked telopeptide of type II collagen, COMP - cartilage oligomeric protein, PIIANP - N-propeptide of collagen IIA, KL - Kellgren-Lawrence, KOOS –

Serum OA biomarkers in ADVANCE

Knee Injury and Osteoarthritis Outcome Score, 6MWD – Six-minute walk test distance, rOA – radiographic osteoarthritis, Unadj. – unadjusted, Adj. - adjusted

#two-group Student's t †two-group Mann-Whitney-U, dichotomised by presence of radiographic osteoarthritis

^four-group oneway analysis of variance ~four-group Kruskal-Wallis, dichotomised by presence of radiographic osteoarthritis and exposure status

Table 4. Demographic and outcome in whole population data stratified by the self-reporting of knee pain (Pain-/Pain+), further stratified by the presence of radiographic osteoarthritis (rOA-/rOA+)

	Total	Pain-	Pain+	p-value Unadj./ Adj.	Pain-/rOA- n- A-	Pain+/rOA- n- OA-	Pain-/rOA+ n- A+	Pain+/rOA+ n- OA+	p-value Unadj./ Adj.
	N=949	N=587	N=362		N=4 83	N=258	N=1 03	N=104	
Age Mean (SD)	34.3 (± 5.5)	34.1 (± 5.3)	34.6 (± 5.7)	0.268#	33.7 (± 5.1)	33.7 (± 5.4)	36.0 (± 5.9)	36.8 (± 5.8)	<0.001 ^
BMI Mean (SD)	27.6 (± 3.5)	27.2 (± 3.3)	28.3 (± 3.7)	<0.001 #	27.1 (± 3.3)	27.8 (± 3.5)	27.7 (± 3.4)	29.6 (± 3.8)	<0.001 ^
IL1β (ng/l) Median (IQR)	0.0 (0.0- 0.1)	0.0 (0.0- 0.1)	0.0 (0.0- 0.1)	0.195" 0.910"	0.0 (0.0- 0.1)	0.0 (0.0- 0.1)	0.0 (0.0- 0.1)	0.0 (0.0- 0.1)	0.458~ 0.418~
TNFα (ng/l) Mean (SD)	1.9 (± 0.6)	1.9 (± 0.6)	1.9 (± 0.7)	0.887# 0.790#	1.9 (± 0.6)	2.0 (± 0.7)	1.9 (± 0.4)	1.9 (± 0.5)	0.955^ 0.987^
IL17α (ng/l) Median (IQR)	1.3 (1.0- 1.8)	1.3 (1.0- 1.8)	1.3 (1.0- 1.9)	0.802" 0.995"	1.3 (1.0- 1.7)	1.3 (1.0- 1.8)	1.3 (1.0- 2.1)	1.4 (1.0- 2.0)	0.758~ 0.533~
CTXII (ug/l) Median (IQR)	0.2 (0.1- 0.6)	0.2 (0.1- 0.6)	0.2 (0.1- 0.7)	0.739" 0.407"	0.2 (0.1- 0.6)	0.2 (0.1- 0.6)	0.2 (0.1- 0.6)	0.2 (0.1- 0.8)	0.574~ 0.816~
Leptin (ug/l) Median (IQR)	5.6 (3.1- 9.0)	5.2 (2.5- 8.3)	6.0 (3.8- 10.0)	<0.001 " 0.001"	5.1 (2.5- 8.3)	5.7 (3.5- 9.4)	5.8 (3.2- 8.5)	7.4 (4.8- 11.2)	<0.001 ~ 0.008~
COMP (ug/l) Mean (SD)	272.6 (± 87.8)	270.6 (± 85.4)	275.9 (± 91.7)	0.367# 0.615#	267. 7 (± 85.2)	269.8 (± 88.2)	284. 0 (± 85.2)	290.9 (± 98.8)	0.045^ 0.904^
Adipo (mg/l) Mean (SD)	6.4 (± 4.6)	6.7 (± 4.9)	5.9 (± 3.8)	<0.010 # 0.004#	6.6 (± 4.5)	6.2 (± 4.2)	7.0 (± 6.4)	5.2 (± 2.8)	0.012^ 0.019^
PIIANP (ug/l) Median (IQR)	110.2 (74.3- 162.5)	113.2 (76.3- 163.9)	106.8 (72.9- 160.2)	0.115" 0.192"	118. 3 (77. 3-	110.5 (76.3- 166.9)	97.2 (71. 6-	90.8 (65.2- 146.1)	0.206~ 0.122~

Serum OA biomarkers in ADVANCE

					169. 6)		144. 2)		
6MWD	615	629	593	<0.001	629	595	631	587	<0.001
Mean (SD)	(± 106)	(± 99)	(± 113)	#	(± 99)	(± 114)	(± 98)	(± 111)	^

IL – Interleukin, TNF – Tumour Necrosis Factor, CTX-II - C-terminal cross-linked telopeptide of type II collagen, COMP - cartilage oligomeric protein, PIIANP - N-propeptide of collagen IIA, rOA – radiographic osteoarthritis, KL - Kellgren-Lawrence, 6MWD – Six-minute walk test distance, Unadj. – unadjusted, Adj. - adjusted
 #two-group Student's t †two-group Mann-Whitney-U, dichotomised by presence of pain
 ^four-group oneway analysis of variance ~four-group Kruskal-Wallis, dichotomised by the presence of pain and radiographic osteoarthritis

Journal Pre-proof